[go: up one dir, main page]

DE69612465D1 - Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen - Google Patents

Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen

Info

Publication number
DE69612465D1
DE69612465D1 DE69612465T DE69612465T DE69612465D1 DE 69612465 D1 DE69612465 D1 DE 69612465D1 DE 69612465 T DE69612465 T DE 69612465T DE 69612465 T DE69612465 T DE 69612465T DE 69612465 D1 DE69612465 D1 DE 69612465D1
Authority
DE
Germany
Prior art keywords
treatment
chlamydia infections
rifamycin derivatives
rifamycin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69612465T
Other languages
English (en)
Other versions
DE69612465T2 (de
Inventor
Katsuji Yamashita
Kazunori Hosoe
Takayoshi Hidaka
George Todaro
Ribhi M Shawar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of DE69612465D1 publication Critical patent/DE69612465D1/de
Application granted granted Critical
Publication of DE69612465T2 publication Critical patent/DE69612465T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69612465T 1995-12-08 1996-12-06 Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen Expired - Lifetime DE69612465T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32088295 1995-12-08
JP00263496A JP3963976B2 (ja) 1995-12-08 1996-01-10 クラミジア感染症治療剤

Publications (2)

Publication Number Publication Date
DE69612465D1 true DE69612465D1 (de) 2001-05-17
DE69612465T2 DE69612465T2 (de) 2001-08-23

Family

ID=26336071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69612465T Expired - Lifetime DE69612465T2 (de) 1995-12-08 1996-12-06 Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen

Country Status (6)

Country Link
US (1) US5786349A (de)
EP (1) EP0778022B1 (de)
JP (1) JP3963976B2 (de)
CA (1) CA2192255C (de)
DE (1) DE69612465T2 (de)
ES (1) ES2155566T3 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006328080A (ja) * 1995-12-08 2006-12-07 Kaneka Corp クラミジア感染症治療剤
US6316433B1 (en) 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
WO2004034961A2 (en) * 2001-09-06 2004-04-29 Activbiotics, Inc. Antimicrobial agents and uses thereof
EP1453837A4 (de) * 2001-11-21 2007-11-07 Activbiotics Inc Zielgerichtete therapeutika und deren anwendungen
US7078399B2 (en) * 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US20030236265A1 (en) * 2002-05-23 2003-12-25 Sayada Chalom B. Methods of treating bacterial infections and diseases associated therewith
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
JP2006515294A (ja) * 2002-12-12 2006-05-25 アクティブバイオティクス インコーポレイティッド アテローム性動脈硬化症およびその関連疾患を治療または予防するための方法および試薬
WO2004054513A2 (en) * 2002-12-12 2004-07-01 Activbiotics, Inc. Methods and compositions for treating and preventing ear infections
EP1663107A4 (de) * 2003-08-22 2010-06-23 Activbiotics Pharma Llc Rifamycin-analoga und ihre verwendungen
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
JP2007506782A (ja) * 2003-09-25 2007-03-22 アクティブバイオティクス インコーポレイティッド リファラジル製剤
WO2005058231A2 (en) * 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
JP2007516291A (ja) * 2003-12-23 2007-06-21 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびその使用法
CN101437518A (zh) * 2006-04-06 2009-05-20 活跃生物药物学有限公司 药物组合物及其应用
WO2007148714A1 (ja) * 2006-06-21 2007-12-27 Kaneka Corporation リファマイシン誘導体を用いたインプラント
WO2007148713A1 (ja) * 2006-06-21 2007-12-27 Kaneka Corporation リファマイシン誘導体を有効成分とする血管性疾患処置剤または細胞増殖調節剤
MX369758B (es) 2013-05-31 2019-11-20 Genentech Inc Anticuerpos anti-acido teicoico de pared y conjugados.
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
DK3004162T3 (da) 2013-05-31 2020-05-18 Genentech Inc Anti-væg-teichoin-antistoffer og konjugater
CN106659745B (zh) 2014-05-15 2020-05-22 株式会社益力多本社 衣原体传染病预防治疗剂
BR112017011478A2 (pt) 2014-12-03 2018-02-27 Genentech, Inc. composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
BR112017011325A2 (pt) 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690919A (en) * 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS61128621A (ja) 1984-11-27 1986-06-16 Rohm Co Ltd フリツプフロツプ回路
JPS63183587A (ja) 1985-02-05 1988-07-28 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノリフアマイシン誘導体
CA1304363C (en) * 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JP2544488B2 (ja) * 1988-11-01 1996-10-16 鐘淵化学工業株式会社 ３’―ヒドロキシベンゾキサジノリファマイシン誘導体
JP2862912B2 (ja) * 1989-09-14 1999-03-03 鐘淵化学工業株式会社 ５’―（４―プロピルまたは４―イソプロピルピペラジニル）ベンゾキサジノリファマイシン誘導体

Also Published As

Publication number Publication date
CA2192255A1 (en) 1997-06-09
ES2155566T3 (es) 2001-05-16
CA2192255C (en) 2004-07-13
DE69612465T2 (de) 2001-08-23
JP3963976B2 (ja) 2007-08-22
EP0778022B1 (de) 2001-04-11
JPH09216824A (ja) 1997-08-19
EP0778022A1 (de) 1997-06-11
US5786349A (en) 1998-07-28

Similar Documents

Publication Publication Date Title
DE69612465D1 (de) Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
NO974610D0 (no) Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
NO982172D0 (no) Anvendelse av epinastin for behandling av smerter
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
NO982582D0 (no) FremgangsmÕte for behandling av smerte
NO981822D0 (no) Anvendelse av proteinet GAX for behandling av cancer
FI980091A0 (fi) Menetelmä ylijäämäaktiivilietteen käsittelemiseksi
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO982562D0 (no) Sammensetning for behandling av smerte
DE69412178D1 (de) Apparat zur Behandlung von Lagen
BR9610382A (pt) Composição de tratamento do cableo
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
ATA93695A (de) Mittel zur behandlung von strahlenschäden
FI974609L (fi) Uusia heterosyklisiä yhdisteitä kivun hoitoon ja niiden käyttö

Legal Events

Date Code Title Description
8364 No opposition during term of opposition